Mechanistic Studies on the Activation of NO by Iron and Cobalt Complexes

ChemInform ◽  
2007 ◽  
Vol 38 (17) ◽  
Author(s):  
Alicja Franke ◽  
Federico Roncaroli ◽  
Rudi van Eldik
2013 ◽  
Vol 52 (24) ◽  
pp. 14391-14403 ◽  
Author(s):  
Eric S. Wiedner ◽  
Aaron M. Appel ◽  
Daniel L. DuBois ◽  
R. Morris Bullock

2007 ◽  
Vol 2007 (6) ◽  
pp. 765-765
Author(s):  
Alicia Franke ◽  
Federico Roncaroli ◽  
Rudi van Eldik

2007 ◽  
Vol 2007 (6) ◽  
pp. 773-798 ◽  
Author(s):  
Alicja Franke ◽  
Federico Roncaroli ◽  
Rudi van Eldik

2017 ◽  
Vol 2 (27) ◽  
pp. 8197-8206 ◽  
Author(s):  
Sushil Kumar ◽  
Rajeev Gupta

2016 ◽  
Vol 228 (06/07) ◽  
Author(s):  
WP Roos ◽  
M Eich ◽  
S Quiros ◽  
AV Knizhnik ◽  
T Nikolova ◽  
...  

2020 ◽  
Author(s):  
Elisabeth Hofmeister ◽  
Jisoo Woo ◽  
Tobias Ullrich ◽  
Lydia Petermann ◽  
Kevin Hanus ◽  
...  

Cobaloximes and their BF<sub>2</sub>-bridged analogues have emerged as promising non-noble metal catalysts for the photocatalytic hydrogen evolution reaction (HER). Herein we report the serendipitous discovery that double complex salts such as [Co(dmgh)<sub>2</sub>py<sub>2</sub>]<sup>+</sup>[Co(dmgBPh<sub>2</sub>)<sub>2</sub>Cl<sub>2</sub>]<sup>-</sup> can be obtained in good yields by treatment of commercially available [Co(dmgh)<sub>2</sub>pyCl] with triarylboranes. A systematic study on the use of such double complex salts and their single salts with simple counterions as photocatalysts revealed HER activities comparable or superior to existing cobaloxime catalysts and suggests ample opportunities for this compound class in catalyst/photosensitizer dyads and immobilized architectures. Preliminary electrochemical and spectroscopic studies indicate that one key advantage of these charged cobalt complexes is that the reduction potentials as well as the electrostatic interaction with charged photosensitizers can be tuned.


Author(s):  
Jack Rowbotham ◽  
Oliver Lenz ◽  
Holly Reeve ◽  
Kylie Vincent

<p></p><p>Chemicals labelled with the heavy hydrogen isotope deuterium (<sup>2</sup>H) have long been used in chemical and biochemical mechanistic studies, spectroscopy, and as analytical tracers. More recently, demonstration of selectively deuterated drug candidates that exhibit advantageous pharmacological traits has spurred innovations in metal-catalysed <sup>2</sup>H insertion at targeted sites, but asymmetric deuteration remains a key challenge. Here we demonstrate an easy-to-implement biocatalytic deuteration strategy, achieving high chemo-, enantio- and isotopic selectivity, requiring only <sup>2</sup>H<sub>2</sub>O (D<sub>2</sub>O) and unlabelled dihydrogen under ambient conditions. The vast library of enzymes established for NADH-dependent C=O, C=C, and C=N bond reductions have yet to appear in the toolbox of commonly employed <sup>2</sup>H-labelling techniques due to requirements for suitable deuterated reducing equivalents. By facilitating transfer of deuterium atoms from <sup>2</sup>H<sub>2</sub>O solvent to NAD<sup>+</sup>, with H<sub>2</sub> gas as a clean reductant, we open up biocatalysis for asymmetric reductive deuteration as part of a synthetic pathway or in late stage functionalisation. We demonstrate enantioselective deuteration via ketone and alkene reductions and reductive amination, as well as exquisite chemo-control for deuteration of compounds with multiple unsaturated sites.</p><p></p>


Sign in / Sign up

Export Citation Format

Share Document